RevMab

anti-CD20 (human), Rabbit Monoclonal (RM272)

CHF 478.00
In stock
REV-31-1153-00-R100100 µlCHF 478.00
More Information
Product Details
Synonyms B-lymphocyte Surface Antigen B1; Bp35 Leukocyte Surface Antigen Leu-16; Membrane-spanning 4-domains Subfamily A Member 1
Product Type Recombinant Antibody
Properties
Clone RM272
Isotype Rabbit IgG
Source/Host Rabbit
Immunogen/Antigen A peptide corresponding to the C-terminus of human CD20.
Application

Immunohistochemistry (IHC): 1:500-1:1000 dilution
Western Blot (WB): 1:1000-1:2000 dilution

Crossreactivity Human
Specificity

This antibody reacts to the cytoplasmic domain of human CD20.

Purity Protein A purified.
Purity Detail Protein A affinity purified from an animal origin-free culture supernatant.
Concentration N/A
Formulation Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide.
Isotype Negative Control

Rabbit IgG

Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Accession Number P11836
Declaration Manufactured by RevMab Biosciences.
Shipping and Handling
Shipping BLUE ICE
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

CD20 is a non-glycosylated surface phosphoprotein that has a molecular weight range of 33-37 kDa depending on the degree of phosphorylation. CD20 is expressed on mature and most malignant B cells, in a subpopulation of T lymphocytes and follicular dendritic cells. CD20 expression on B cells is synchronous with the expression of surface IgM and it regulates transmembrane calcium conductance, cell cycle progression and B cell proliferation. CD20 is also associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following monoclonal antibody treatment. Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency, B cell non-Hodgkin's lymphoma or chronic lymphocytic leukaemia (CLL).

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.